RSABE - ANVISA [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2018-09-22 14:11 (1418 d 01:31 ago) – Posting: # 19298
Views: 1,825

Dear Maitri,

» Can any one comment on acceptability of Reference Scale Bioequivalence Approach for ANVISA ( Regulatory agency of Brazil) for highly variable drugs? Do they accept RSABE study design for Highly variable drug compunds?

Have you ever discovered the search field in the upper right corner of the forum?

Use it and you will find some threads dealing with the ANVISA specifications for scaled ABE. E.g. this one.

What do you think: If they have specifications for scaled ABE, do they accept studies using that approach?

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
22,291 posts in 4,666 threads, 1,584 registered users;
online 9 (2 registered, 7 guests [including 4 identified bots]).
Forum time: Wednesday 15:42 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5